[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"consciousness-level-altered\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:consciousness-level-altered":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,49,71],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100516331","recovery-from-dexmedetomidine-induced-unconsciousness-100516331",false,"NCT06003127","REcovery From DEXmedetomidine-induced Unconsciousness","REDEX","Inclusion Criteria:\n\n* Between the ages of 18 to 65\n* Normal body weight and habitus, body mass index (BMI) 18 to 30 kg\u002Fm2\n* Non-smoker\n* No history of taking stimulants or substance abuse\n* For women: either use of hormonal contraception, or \\> 45 years old and last menstrual period \\> 12 months ago in the absence of any contraceptives.\n* American Society of Anesthesiologists (ASA) physical status classification 1 (ASA 1)\n* Fluent in English (sufficient to communicate with the study team and understand the consent form)\n\nExclusion Criteria:\n\n* Neurologic: epilepsy or positive history of a seizure, stroke, central disorders of hypersomnolence, neuroimmunological disorder (e.g. multiple sclerosis), Meniere's disease, Parkinson's disease, peripheral neuropathy, no significant visual or hearing impairments, findings in the clinical examination suggesting a neurologic disorder\n* Psychiatric: history or treatment for an active psychiatric problem (including Attention-Deficit \u002F Hyperactivity Disorder (ADHD) and anxiety disorder)\n* Cardiovascular: hypertension, symptomatic hypotension or bradycardia, myocardial infarction, coronary artery disease, peripheral vascular disease, dysrhythmias, congestive heart failure, cardiomyopathy, valvular disease, familial history of sudden cardiac death\n* Respiratory: bronchitis, asthma, chronic obstructive pulmonary disease, smoking, shortness of breath, sleep apnea\n* Gastrointestinal: esophageal reflux, hiatal hernia, ulcer\n* Hepatic: hepatitis, jaundice, ascites\n* Renal: acute or chronic severe renal insufficiency\n* Reproductive: pregnancy, breast-feeding\n* Endocrine: diabetes, thyroid disease, adrenal gland disease\n* Hematologic: blood dyscrasias, anemia, coagulopathies\n* Musculoskeletal: prior surgery or trauma to head neck or face, arthritis, personal or family history of malignant hyperthermia\n* Medications: regular use of prescription and non-prescription medications expected to affect central nervous function, anticoagulant or thrombocyte-aggregation inhibiting therapy; exception: oral hormonal contraception\n* Allergies: dexmedetomidine, phenylephrine, betablockers (including labetalol and esmolol), hydralazine, glycopyrrolate\n\nPotential participants will not be enrolled in our study if they fail to pass a standard drug screening test (toxicology).",true,"ALL","18 Years","65 Years",{"count":21,"type":22},12,"ESTIMATED","INTERVENTIONAL",[25],"NA","This pilot study in healthy volunteers aims to determine if biological sex has an impact on recovery from dexmedetomidine-induced unconsciousness, and if transcranial magnetic stimulation combined with electroencephalography (TMS-EEG) can be used to measure brain complexity during dexmedetomidine sedation without arousing study participants.",[28,29,30],"Anesthesia","Healthy","Consciousness, Level Altered",[32,33,34,35],"Dexmedetomidine","EEG","Transcranial magnetic stimulation","Cognition","RECRUITING","2026-01-20",{"date":39,"type":40},"2026-01-22","ACTUAL",{"date":42,"type":40},"2024-11-15",{"date":44,"type":22},"2026-12",{"name":46,"class":47},"Massachusetts General Hospital","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":19,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":48},"100604144","phase-4-the-electroencephalographic-mechanisms-of-anesthesia-and-human-consciousness-100604144","NCT07145697","The Electroencephalographic Mechanisms of Anesthesia and Human Consciousness","Inclusion Criteria:\n\n1. Age range: 1 - 65 years old\n2. BMI: 18.5 - 25.0 kg\u002Fm²\n3. ASA physical status classification: I - III\n4. Patients diagnosed with drug - refractory epilepsy who, after long - term monitoring of epileptic seizures, require stereo-electroencephalography (SEEG) electrode implantation based on the clinical need for monitoring their epilepsy.\n5. Patients voluntarily participate in this study and sign a written informed consent form.\n\nExclusion Criteria:\n\n1. Patients with severe arrhythmia or other organic heart diseases;\n2. Patients with comorbid obstructive sleep apnea-hypopnea syndrome (OSAHS);\n3. Patients with hepatic or renal dysfunction; those with a history of immunodeficiency diseases , or a history of cancer\u002Fmalignant tumors, or a history of autoimmune diseases, or severe cardiovascular and cerebrovascular diseases, or other diseases that may significantly reduce life expectancy;\n4. Patients with any history of diseases that may affect protocol compliance (such as severe mental disorders, disturbance of consciousness; cognitive dysfunction, drug abuse or addiction, etc.);\n5. Pregnant or lactating women, or those of childbearing potential who are unwilling\u002Funable to take effective contraceptive measures;\n6. Patients with known allergies to the ingredients contained in the drugs used in this study;\n7. Patients who have participated in any drug clinical trial within 6 months before the screening examination;\n8. Patients who are deemed unsuitable to participate in this study by the researcher.","3 Years",{"count":57,"type":22},30,[59],"PHASE4","In the field of general anesthesia research, the neural mechanism underlying the loss of consciousness has long been a highly core issue. It remains unclear what consciousness is and how it emerges from brain activity. By studying anesthesia and sleep, the investigators aim to reveal what happens in the brain when consciousness is lost and when it returns.\n\nDexmedetomidine, a widely used drug in clinical anesthetic practice, plays an important role in the anesthetic process due to its unique pharmacological properties. It hardly causes respiratory depression during the sedative and hypnotic process, which makes it occupy an important position in clinical anesthetic regimens.\n\nThe emergence of stereoelectroencephalography (SEEG) technology has brought new opportunities for research on anesthesia mechanisms. Compared with traditional electroencephalographic (EEG), SEEG can directly penetrate into deep brain structures to record electrical activities, enabling precise localization of brain regions closely related to consciousness regulation.\n\nAt present, although there have been some studies on the effects of dexmedetomidine on EEG activities, there are still many deficiencies. Most studies have focused on simple spectral analysis of EEG signals or observations of limited brain regions, lacking comprehensive multi-dimensional research on functional connectivity between brain regions, microstates, and complexity. Through monitoring key brain regions, the SEEG technology can obtain more targeted and accurate information, thereby providing strong support for comprehensively revealing the neural mechanisms of dexmedetomidine-induced loss of consciousness.",[30],"2025-08-21",{"date":64,"type":40},"2025-08-28",{"date":66,"type":40},"2025-04-10",{"date":68,"type":22},"2027-06-30",{"name":70,"class":47},"Guangzhou General Hospital of Guangzhou Military Command",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":23,"phases":81,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":48},"100554740","phase-3-the-effect-of-phosphocreatine-on-medical-emergency-team-met-treated-patients-100554740","NCT06503016","The Effect of phoSPHocreatine on mEdical Emergency Team (Met) tREated Patients","The Effect of phoSPHocreatine on mEdical Emergency Team (Met) tREated Patients: a Randomized Clinical Trial Protocol","SPHERE","Inclusion Criteria:\n\n1. Admitted in hospital (but outside ICU)\n2. Age\\>=18 years\n3. Written informed consent\n4. Serum creatinine \\\u003C=2 mg\u002Fdl\n5. Patient with impending or underlying cardiac failure or cardiac arrest, irrespectively of the primitive organ failure, and the Medical Emergency Team (MET) is called upon at least one of the following:\n\n   1. Threatened airways;\n   2. Respiratory arrest;\n   3. Respiratory rate \\\u003C5 or \\>36 breaths per min;\n   4. Pulse rate \\\u003C40 or \\>140 beats per min;\n   5. Systolic blood pressure \\\u003C 90 mm Hg;\n   6. Sudden fall in level of consciousness;\n   7. Fall in Glasgow coma scale of \\> 2 points.\n\nExclusion Criteria:\n\n1. Age \\\u003C 18 years;\n2. Ongoing cardiac massage;\n3. Current hospital admission from a care nursing facility;\n4. Planned discharge to a care nursing facility;\n5. Reasons for withdrawal of life-sustaining therapy;\n6. History of kidney transplantation;\n7. Solitary kidney (by any reason);\n8. Serum Creatinine \\> 2 mg\u002Fdl;\n9. Immediate need for ICU admission;\n10. Known allergy to PCr;\n11. Pregnancy;\n12. Previous enrollment and randomization into this trial;\n13. Administration of PCr in the previous 30 day.",{"count":80,"type":22},400,[82],"PHASE3","Unexpected deaths and unplanned intensive care unit (ICU) admissions are common during hospital stay and are often preceded by warning abnormalities in patients' vital signs. These abnormalities trigger Medical Emergency Team (MET) activation and up to 15% of patients visited by the MET is admitted to the ICU with an overall hospital stay after the MET intervention of approximately 2 weeks. Phosphocreatine (PCr) is a natural energy-buffering molecule associated with signals of mortality reduction in patients with acute cardiac conditions (according to meta-analytic finding from our group) and with encouraging beneficial effects on other acute organ failures (e.g. brain). The investigators designed a multi-center, randomized, placebo-controlled trial to confirm the promising beneficial effects of PCr in hospitalized patients. The investigators expects a reduction in hospital stay (measured as an increase in days alive and out of hospital at 30 days) when PCr is added to standard treatment in patients requiring MET intervention.",[85,30,86,87,88,89,90,91,92,93],"Hypotension","Airway Disease","Respiratory Failure","Tachypnea","Bradypnea","Tachycardia","Bradycardia","Cardiac Failure","Cardiac Arrest","2025-08-05",{"date":96,"type":40},"2025-08-06",{"date":98,"type":40},"2024-10-08",{"date":100,"type":22},"2026-07",{"name":102,"class":47},"Università Vita-Salute San Raffaele"]